Vyne Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Vyne Therapeutics sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials none currently recruiting 15 completed top decile by trial count

Vyne Therapeutics: 18 sponsored US clinical trials, none currently recruiting.

Vyne Therapeutics sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 8 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-segmental Vitiligo, with 1 trials.

Top-decile sponsor footprint

Vyne Therapeutics ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

15 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

18 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
COMPLETED Phase 1

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
COMPLETED Phase 2

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
COMPLETED Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

NCT03841331
COMPLETED Phase 1

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

NCT03743038
COMPLETED Phase 3

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

NCT03546816
TERMINATED Phase 3

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
COMPLETED Phase 2

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

NCT03343639
COMPLETED Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

NCT03282591
COMPLETED Phase 3

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
COMPLETED Phase 3

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
COMPLETED Phase 3

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
COMPLETED Phase 3

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
COMPLETED Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206
TERMINATED Phase 2

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

NCT02975271
COMPLETED Phase 3

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
COMPLETED Phase 3

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815267
COMPLETED Phase 2

VPD-737 for Treatment of Chronic Pruritus

NCT01951274

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 8
Phase 3 8

Therapeutic Areas

Non-segmental Vitiligo 1

How the Vyne Therapeutics archive is shaped

18 indexed studies, none listed as recruiting (0% open); 15 completed (83%).

Phase mix: 8 late (III/IV) vs 10 early (I/II) (balanced across stages).

Top condition: Non-segmental Vitiligo (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Vyne Therapeutics: archived-pipeline peers nationwide

Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Vyne Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share Vyne TherapeuticsADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation Center10xBio22nd Century Group23andMe3-C Institute for Social Development
Vyne Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vyne Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Vyne Therapeutics page

18 registered trials is a research-attention snapshot, not an endorsement of Vyne Therapeutics or any single study.

  • None of Vyne Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Non-segmental Vitiligo is the condition Vyne Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-segmental Vitiligo trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vyne Therapeutics pipeline card: 18 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.